Abstract

Microvascular disease is a prominent feature of systemic sclerosis (SSc) and leads to Raynaud's phenomenon, pulmonary arterial hypertension, and scleroderma renal crisis. The presence of macrovascular disease is less well established, and, in particular, it is not known whether the prevalence of coronary heart disease in SSc is increased. Furthermore, in terms of cardiac involvement in SSc, there remains conjecture about the relative contributions of atherosclerotic macrovascular disease and myocardial microvascular disease. In this review, we summarize the literature describing cardiovascular disease in SSc, discuss the pathophysiological mechanisms common to SSc and atherosclerosis, and review the surrogate markers of cardiovascular disease which have been examined in SSc. Proposed mediators of the vasculopathy of SSc which have also been implicated in atherosclerosis include endothelial dysfunction, a reduced number of circulating endothelial progenitor cells, and an increased number of microparticles. Excess cardiovascular risk in SSc is suggested by increased arterial stiffness and carotid intima thickening and reduced flow-mediated dilatation. Cohort studies of adequate size are required to resolve whether this translates into an increased incidence of cardiovascular events in patients with SSc.

Highlights

  • Patients with systemic inflammatory conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) have been shown to develop premature and accelerated atherosclerosis [1,2], but it remains unclear macrovascular disease was not originally considered a feature of systemic sclerosis (SSc), multiple studies have revealed an increased prevalence of large-vessel disease of the upper and lower limbs in patients with SSc [3,4]

  • This temporal change is reflected in an analysis of mortality over a 30-year period from 1972 to 2002, in which 10-year survival improved from 54% to 66% and non-SSc-related deaths increased from 20% to 50% of all deaths [12]

  • Nevskaya and colleagues [64] examined the relationship between cardiovascular disease and endothelial progenitor cell (EPC) in 40 patients with SSc and found that a decreased EPC count correlated with endothelial dysfunction, as measured by Flow-mediated dilatation (FMD)

Read more

Summary

Introduction

Patients with systemic inflammatory conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) have been shown to develop premature and accelerated atherosclerosis [1,2], but it remains unclear. Macrovascular disease was not originally considered a feature of SSc, multiple studies have revealed an increased prevalence of large-vessel disease of the upper and lower limbs in patients with SSc [3,4]. The prevalence of coronary artery and cerebrovascular disease in SSc, remains unclear. The purposes of this review are to summarize the evidence for macrovascular disease, cardiovascular risk factors, and surrogate measures of cardiovascular disease in SSc and to explore potential pathogenic mechanisms of accelerated atherosclerosis in patients with SSc

Clinical cardiovascular disease
Outcomea Other findings
No difference was found between patients with
Potential mechanisms of cardiovascular disease in systemic sclerosis
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call